IL152996A0 - Novel interferon for the treatment of multiple sclerosis - Google Patents

Novel interferon for the treatment of multiple sclerosis

Info

Publication number
IL152996A0
IL152996A0 IL15299601A IL15299601A IL152996A0 IL 152996 A0 IL152996 A0 IL 152996A0 IL 15299601 A IL15299601 A IL 15299601A IL 15299601 A IL15299601 A IL 15299601A IL 152996 A0 IL152996 A0 IL 152996A0
Authority
IL
Israel
Prior art keywords
treatment
multiple sclerosis
novel interferon
interferon
novel
Prior art date
Application number
IL15299601A
Other languages
English (en)
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of IL152996A0 publication Critical patent/IL152996A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL15299601A 2000-06-16 2001-06-18 Novel interferon for the treatment of multiple sclerosis IL152996A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (fr) 2000-06-16 2001-06-18 Nouvel interferon destine au traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
IL152996A0 true IL152996A0 (en) 2003-06-24

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15299601A IL152996A0 (en) 2000-06-16 2001-06-18 Novel interferon for the treatment of multiple sclerosis

Country Status (22)

Country Link
US (1) US20020025304A1 (fr)
EP (1) EP1289541A2 (fr)
JP (1) JP2004505021A (fr)
KR (1) KR20030009529A (fr)
CN (1) CN1436086A (fr)
AU (1) AU2001267099A1 (fr)
BG (1) BG107370A (fr)
BR (1) BR0111852A (fr)
CA (1) CA2413077A1 (fr)
CZ (1) CZ20024094A3 (fr)
EE (1) EE200200693A (fr)
HU (1) HUP0300787A2 (fr)
IL (1) IL152996A0 (fr)
LT (1) LT2002123A (fr)
MX (1) MXPA02012308A (fr)
NO (1) NO20025964L (fr)
NZ (1) NZ522849A (fr)
PL (1) PL359562A1 (fr)
RU (1) RU2003100517A (fr)
SI (1) SI21080A (fr)
SK (1) SK17612002A3 (fr)
WO (1) WO2001095929A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046365A2 (fr) * 2002-11-18 2004-06-03 Maxygen, Inc. Polypeptides et conjugues interferon-alpha
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (fr) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Mise-à-jour d'instructions de données
EP2536435B1 (fr) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Homologue de singe d'interféron oméga humain
US10988538B2 (en) 2016-02-05 2021-04-27 Orionis Biosciences BV Bispecific signaling agents and uses thereof
EP3576765A4 (fr) 2017-02-06 2020-12-02 Orionis Biosciences, Inc. Interféron d'ingénierie ciblé et utilisations de ce dernier
JP7476467B2 (ja) 2017-02-06 2024-05-01 オリオンズ バイオサイエンス ビーブイ 標的化キメラタンパク質及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
AU761577C (en) * 1997-12-08 2004-02-05 Genentech Inc. Human interferon-epsilon: a type I interferon
EE200000694A (et) * 1998-05-29 2002-06-17 Biogen, Inc. Inimese rekombinantse iterferooni beeta-1a (IFN-ß-1a) formulatsioon
IL142061A0 (en) * 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon
WO2001079289A2 (fr) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Interferon humain, zinf2

Also Published As

Publication number Publication date
KR20030009529A (ko) 2003-01-29
SK17612002A3 (sk) 2003-08-05
NZ522849A (en) 2004-05-28
NO20025964D0 (no) 2002-12-12
EE200200693A (et) 2004-06-15
MXPA02012308A (es) 2003-04-25
BR0111852A (pt) 2003-05-20
SI21080A (sl) 2003-06-30
HUP0300787A2 (hu) 2003-07-28
WO2001095929A2 (fr) 2001-12-20
BG107370A (en) 2003-11-28
PL359562A1 (en) 2004-08-23
EP1289541A2 (fr) 2003-03-12
CN1436086A (zh) 2003-08-13
JP2004505021A (ja) 2004-02-19
CA2413077A1 (fr) 2001-12-20
NO20025964L (no) 2003-02-14
US20020025304A1 (en) 2002-02-28
LT2002123A (en) 2003-06-25
RU2003100517A (ru) 2004-06-27
CZ20024094A3 (cs) 2003-05-14
AU2001267099A1 (en) 2001-12-24
WO2001095929A3 (fr) 2002-10-10

Similar Documents

Publication Publication Date Title
IL196301A0 (en) Medicament for the treatment of hapatitis c
IL145470A0 (en) Compositions for the treatment of immune diseases
EP1390029A4 (fr) Phenylindoles pour le traitement de l'infection par le vih
GB0113751D0 (en) Surface treatment
EG25829A (en) Novel treatment
IL156963A0 (en) Processes for the purification of higher diamondoids and compositions comprising such diamondoids
GB0030845D0 (en) Novel treatment
GB0226147D0 (en) Treatment for multiple sclerosis
IL152996A0 (en) Novel interferon for the treatment of multiple sclerosis
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
EP1435979A4 (fr) Methodes de traitement de la sclerose en plaques
HK1066022A1 (en) Use of 1,1,1,3,3-pentafluorobutan
GB0114231D0 (en) Treatment of multiple sclerosis
GB0124710D0 (en) Therapeutic composition
PL350883A1 (en) One-track roller-board
GB0103031D0 (en) Novel treatment
GB0029125D0 (en) Novel treatment
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
GB0019728D0 (en) Novel treatment
HU0104370D0 (en) Honeyed schnaps of oerseg
GB9817095D0 (en) Compounds for the treatment of multiple sclerosis
AP2007003992A0 (en) 3'-Prodrugs of 2'-deoxy-beta-l-nucleosides
AU148765S (en) Set of switches
AU147140S (en) Set of trays